Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01421472 · ClinicalTrials.gov registry record · Phase 2
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
A Phase 2 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
NCT01421472 is a Phase 2 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 196 participants.
The verdict
NCT01421472, a Phase 2 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
Study Summary
To demonstrate whether addition of MM-121 to paclitaxel is more effective than treatment with paclitaxel alone, when administered as part of the neoadjuvant treatment in Her2 negative locally advanced operable breast cancer patients.
Interventions
- DRUG Paclitaxel
- DRUG MM-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01421472
The ClinicalTrials.gov registry entry for NCT01421472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01421472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01421472 about?
NCT01421472 is a clinical study titled "A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer". To demonstrate whether addition of MM-121 to paclitaxel is more effective than treatment with paclitaxel alone, when administered as part of the neoadjuvant treatment in Her2 negative locally advanced operable breast cancer patients.
What is the current status of trial NCT01421472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2011-08. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01421472?
The interventions under investigation include: Paclitaxel (DRUG), MM-121 (DRUG).
Who is sponsoring clinical trial NCT01421472?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.